After a public and passionate debate over its funding of Planned Parenthood, breast cancer charity Susan G. Komen for the Cure has become embroiled in another controversy, this one over its role in funding embryonic stem cell (ESC) research.
Last week, an online pro-life publication, LifeNews.com, published a story claiming that the Komen foundation had stopped funding ESC research for breast cancer, ScienceInsider reported. The article was the result of a confusing swarm of online reports: Last year, a tax analysis touted by LifeNews.com said that the charity gave $12 million in research funds to five institutions where human embryonic stem cell research was conducted. Then, in November, the foundation posted a statement on its website saying that it does not support embryonic stem cell research. This response led to the story claiming that the organization had stopped funding the $12 million in research grants.
The Komen foundation has since cleared up the issue. In a statement made on Sunday (5 February), the organization said that ESCs have not been used in any research funded by Komen, and the organization has not de-funded any grantee based on ESC research being performed at his or her institution.